Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms UM ERD-4001, UMERD-4001, UM-ERD 4001 + [1] |
Target |
Mechanism ERα antagonists(Estrogen receptor alpha antagonists) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HER2-negative breast cancer | Preclinical | US | 09 Apr 2024 | |
HER2-negative breast cancer | Preclinical | US | 09 Apr 2024 | |
Hormone receptor positive breast cancer | Preclinical | US | 09 Apr 2024 | |
Hormone receptor positive breast cancer | Preclinical | US | 09 Apr 2024 | |
Estrogen receptor positive breast cancer | Preclinical | US | 22 Mar 2024 | |
Estrogen receptor positive breast cancer | Preclinical | US | 22 Mar 2024 |